PP Capital

Reveal Biosciences, Inc. is a San Diego-based computational pathology company founded in 2012 that specializes in tissue-based research and diagnostics. The company employs artificial intelligence to enhance the diagnosis of diseases through the analysis of large whole slide microscope images. Its offerings include precision histology, in situ hybridization, whole slide imaging, image analysis, commercial antibody validation, antibody optimization, and immunohistochemistry. Reveal serves a diverse clientele, including pharmaceutical and biotechnology companies, academic institutions, and government agencies worldwide. By combining a histopathology laboratory with machine learning technologies, Reveal aims to improve the accuracy, speed, and cost-effectiveness of disease diagnosis, enabling clients to better analyze tissue samples for applications in patient stratification, disease diagnosis, prognostics, and tumor detection.

Sealife Pharma is a marine biopharmaceutical company specializing in the discovery and development of novel bioactive compounds derived from marine fungi. The company's primary focus is on creating new antibiotics to address multi-drug resistant infections, including those caused by pathogens such as Pseudomonas aeruginosa, Acinetobacter baumannii, and various resistant Streptococcus pneumoniae strains. In addition to antibiotics, Sealife Pharma is engaged in the development of antimicrobials and disinfection agents, aiming to provide effective medical solutions with minimal side effects. By leveraging the unique chemical diversity found in marine ecosystems, Sealife Pharma seeks to contribute to the fight against antibiotic resistance and enhance the therapeutic options available to healthcare providers.

Anagnostics specializes in developing systems and tests for research and clinical in-vitro-diagnostics. Their goal is to provide solutions for unmet needs especially in protein and infectious disease diagnostics